GSK 6-K
GSK plc (GSK)
6-K
2026-02-11
For: 2026-02-11
View Original
Added on
July 04, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2026
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the 'Company')
Vesting of Conditional Share Awards under the Share Value Plan and Sale of Ordinary Shares and American Depositary Shares
This notification sets out the vesting details for Persons Discharging Managerial Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') of conditional awards over Ordinary Shares and American Depositary Shares ('ADS') made in 2023 under the GSK Share Value Plan and the subsequent sale of Ordinary Shares and ADS to meet tax liabilities. The awards, which were conditional on continued employment with the GSK group, vested on 9 February 2026.
Transaction notification
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
|---|---|---|---|---|---|
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's<br>Share Value Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Lynn Baxter | |||
| b) | Position/status | President, Europe | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 4,084 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's<br>Share Value Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Mike Crichton | |||
| b) | Position/status | President, International | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 3,920 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The vesting of ADS awarded in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $0.00 | 10,658 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Maya Martinez-Davis | |||
| b) | Position/status | President, US | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | American Depositary Shares ('ADS')<br><br><br>ISIN: US37733W2044 | |||
| b) | Nature<br>of the transaction | The sale of ADS to meet tax liabilities on the vesting of<br>awards granted in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| $59.0729 | 2,789 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's<br>Share Value Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 23,120 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Nina Mojas | |||
| b) | Position/status | President, Global Product Strategy | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 6,104 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP & Company Secretary | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's<br>Share Value Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Victoria Whyte | |||
| b) | Position/status | SVP & Company Secretary | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 4,724 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The vesting of Ordinary Shares awarded in 2023 under the Company's<br>Share Value Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £0.00 | 10,050 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | N/A | |||
| 1. | Details of PDMR/person closely associated with them<br>('PCA') | ||||
| --- | --- | --- | --- | --- | --- |
| a) | Name | Neil Falkingham | |||
| b) | Position/status | PCA of Lynn Baxter (President, Europe) | |||
| c) | Initial<br>notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant,<br>auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each<br>type of instrument; (ii) each type of transaction; (iii) each date;<br>and (iv) each place where transaction(s) has been<br>conducted | ||||
| a) | Description<br>of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary<br>Shares')<br><br><br>ISIN: GB00BN7SWP63 | |||
| b) | Nature<br>of the transaction | The sale of Ordinary Shares to meet tax liabilities on the vesting<br>of awards granted in 2023 under the Company's Share Value<br>Plan | |||
| c) | Price(s)<br>and volume(s) | Price(s) | Volume(s) | ||
| £21.9082 | 4,373 | ||||
| d) | Aggregated<br>information | N/A (single transaction) | |||
| Aggregated<br>volume<br><br>Price | |||||
| e) | Date<br>of the transaction | 2026-02-09 | |||
| f) | Place<br>of the transaction | London Stock Exchange (XLON) |
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: February<br>11, 2026 | |
| By:/s/ VICTORIA<br>WHYTE<br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |